Cargando…

Identification of MS-specific serum miRNAs in an international multicenter study

OBJECTIVE: To identify circulating microRNAs (miRNAs) linked to disease, disease stage, and disability in MS across cohorts. METHODS: Samples were obtained from the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB, Boston, MA), EPIC (San Francisco, CA), AMIR (Beirut, Lebanon) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regev, Keren, Healy, Brian C., Paul, Anu, Diaz-Cruz, Camilo, Mazzola, Maria Antonietta, Raheja, Radhika, Glanz, Bonnie I., Kivisäkk, Pia, Chitnis, Tanuja, Jagodic, Maja, Piehl, Fredrik, Olsson, Tomas, Khademi, Mohsen, Hauser, Stephen, Oksenberg, Jorge, Khoury, Samia J., Weiner, Howard L., Gandhi, Roopali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117192/ https://www.ncbi.nlm.nih.gov/pubmed/30175165 http://dx.doi.org/10.1212/NXI.0000000000000491

Ejemplares similares

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation
por: Mazzola, Maria Antonietta, et al.
Publicado: (2015)

Increased leptin and A-FABP levels in relapsing and progressive forms of MS
por: Messina, Silvia, et al.
Publicado: (2013)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis
por: Kivisäkk, Pia, et al.
Publicado: (2014)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
por: Bove, Riley, et al.
Publicado: (2013)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance
por: Fujiwara, Mai, et al.
Publicado: (2022)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
por: Bergman, Petra, et al.
Publicado: (2016)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019)

Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS
por: Rothhammer, Veit, et al.
Publicado: (2017)

Alterations of the human gut microbiome in multiple sclerosis
por: Jangi, Sushrut, et al.
Publicado: (2016)

Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases
por: Saxena, Shrishti, et al.
Publicado: (2020)

History of fatigue in multiple sclerosis is associated with grey matter atrophy
por: Palotai, Miklos, et al.
Publicado: (2019)

Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)

Risk attitudes and risk perceptions in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2016)

A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis
por: Xia, Zongqi, et al.
Publicado: (2010)

Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course
por: Bove, Riley, et al.
Publicado: (2013)

Defective Induction of IL-27-Mediated Immunoregulation by Myeloid DCs in Multiple Sclerosis
por: von Glehn, Felipe, et al.
Publicado: (2023)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum
por: Barro, Christian, et al.
Publicado: (2021)

MRI phenotypes in MS: Longitudinal changes and miRNA signatures
por: Hemond, Christopher C., et al.
Publicado: (2019)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers
por: Huang, Jesse, et al.
Publicado: (2021)

Blood neurofilament light: a critical review of its application to neurologic disease
por: Barro, Christian, et al.
Publicado: (2020)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis
por: Bakshi, Rohit, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_39l00sv34c7li4vsudolvcfk9a